Newsroom
Latest News
News
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10
Salt Lake City, May 2, 2022 —Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and…
News
SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD
Sera Prognostics announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.
News
Sera Prognostics Reports Fourth Quarter 2021 Financial Results
Salt Lake City – March 29, 2022 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to…
News
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Factors at SRI Annual Meeting
Salt Lake City, March 18, 2022 —Sera Prognostics Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today presented…
News
Sera Prognostics To Present At Upcoming March Investor Conferences
Salt Lake City – March 3, 2022 – Sera Prognostics Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced…
News
Sera Prognostics Presentation Rescheduled For Citi 2022 Healthcare Conference
Salt Lake City – February 17, 2022 – Sera Prognostics Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced…
News
Sera Prognostics To Present At Upcoming February Investor Conferences
Salt Lake City – February 7, 2022 – Sera Prognostics Inc., The PregnancyCompany ® (Nasdaq: SERA), focused on improving maternal and neonatal healthby providing innovative pregnancy biomarker information to doctors and patients,today announced…
News
Sera Prognostics Announces New Agreement With Multiplan, Expanding Patient Access To The PreTRM® Test
Feb 1, 2022, Sera Prognostics announced the execution of an agreement with MultiPlan, for participation in its PHCS and MultiPlan Networks.
News
Sera Prognostics Added To Nasdaq Biotechnology Index
Dec 15, Sera Prognostics announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI).
News
Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm Birth
Dec. 2, 2021, Sera Prognostics announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.